The present disclosure provides methods for treating Post-Traumatic Stress Disorder (PTSD) and other neurological disorders in a subject, comprising administering to the subject an effective amount of a composition comprising ghrelin.

The present disclosure provides methods for treating Post-Traumatic Stress Disorder (PTSD) and other neurological disorders in a subject, comprising administering to the subject an effective amount of a composition comprising ghrelin.

The present invention relates to compositions and local delivery methods to increase pelvic tissue integrity and the treatment, reduction and/or prevention of stress urinary incontinence [SUI] and fecal incontinence [FI] due to weakness in pelvic floor. The treatment comprises of growth and/or repair promoting compound(s) [GRPCs] including but not limited to androgens, androgen receptor modulators, ghrelin, a ghrelin analog, an estrogen, an estrogen receptor modulator, or a combination thereof for delivery into the vagina, anorectal canal or through the mucosa in these viscera to treat pelvic floor disorders.

The present invention relates to compositions and local delivery methods to increase pelvic tissue integrity and the treatment, reduction and/or prevention of stress urinary incontinence [SUI] and fecal incontinence [FI] due to weakness in pelvic floor. The treatment comprises of growth and/or repair promoting compound(s) [GRPCs] including but not limited to androgens, androgen receptor modulators, ghrelin, a ghrelin analog, an estrogen, an estrogen receptor modulator, or a combination thereof for delivery into the vagina, anorectal canal or through the mucosa in these viscera to treat pelvic floor disorders.

The disclosure provides a method of obtaining a population of cardiomyogenic precursor cells. The method comprises (a) differentiating induced pluripotent stem cells (iPSCs) to iPSC-derived cardiac precursor cells; and (b) isolating cardiac precursor cells expressing mammalian growth hormone-releasing hormone receptor (GHRHR) to obtain a population of iPSC-derived cardiomyogenic precursor cells.

The disclosure provides a method of obtaining a population of cardiomyogenic precursor cells. The method comprises (a) differentiating induced pluripotent stem cells (iPSCs) to iPSC-derived cardiac precursor cells; and (b) isolating cardiac precursor cells expressing mammalian growth hormone-releasing hormone receptor (GHRHR) to obtain a population of iPSC-derived cardiomyogenic precursor cells.

The present invention relates to novel injectable presentations, kits or syringes comprising a composition with sustained or controlled release of lanreotide or one of the salts thereof. The compositions of lanreotide or one of the salts thereof are packaged in a syringe having a diameter greater than 3.00 mm and provided with a needle having an outer diameter no greater than 1.00 mm.

The present invention relates to novel injectable presentations, kits or syringes comprising a composition with sustained or controlled release of lanreotide or one of the salts thereof. The compositions of lanreotide or one of the salts thereof are packaged in a syringe having a diameter greater than 3.00 mm and provided with a needle having an outer diameter no greater than 1.00 mm.

The present invention relates to a pharmaceutical composition including: a pharmaceutically effective amount of at least one peptide; and a pharmaceutically acceptable amount of a combination of: (a) at least one metal in form of any or a combination of a salt thereof and a complex thereof; and (b) at least one reducing agent, wherein, the at least one metal is selected from any or a combination of: vanadium, chromium and manganese, and wherein the combination of (a) at least one metal in form of any or a combination of a salt and a complex and (b) at least one reducing agent affords protection, at least in part, to the at least one peptide from protcolytic degradation upon ingestion thereof.

The present invention relates to a pharmaceutical composition including: a pharmaceutically effective amount of at least one peptide; and a pharmaceutically acceptable amount of a combination of: (a) at least one metal in form of any or a combination of a salt thereof and a complex thereof; and (b) at least one reducing agent, wherein, the at least one metal is selected from any or a combination of: vanadium, chromium and manganese, and wherein the combination of (a) at least one metal in form of any or a combination of a salt and a complex and (b) at least one reducing agent affords protection, at least in part, to the at least one peptide from protcolytic degradation upon ingestion thereof.